Our understanding of the genetics of acute myeloid leukemia (AML) development from
myelodysplastic syndrome (MDS) has advanced significantly as a result of next-generation …

The myelodysplastic syndromes are clonal hematologic disorders characterized clinically
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …

Despite genetic heterogeneity, myelodysplastic syndromes (MDSs) share features of
cytological dysplasia and ineffective hematopoiesis. We report that a hallmark of MDSs is …

Myelodysplastic syndromes (MDS) are a group of disorders characterized by variable
cytopenias and ineffective hematopoiesis. Hematopoietic stem cells (HSCs) and myeloid …

Caspases are cysteine proteases involved in apoptosis and cytokine maturation. In
erythroblasts, keratinocytes, and lens epithelial cells undergoing differentiation, enucleation …

Myelodysplastic syndromes (MDS) are malignant clonal disorders of haematopoietic stem
cells and their microenvironment, affecting older individuals (median age∼ 70 years) …

Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting
at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped …

Chronic inflammation with aging (“inflammaging”) plays a prominent role in the
pathogenesis of myeloid malignancies. Aberrant inflammatory activity affects many different …

Myelodysplastic syndromes are associated with a risk of severe infections. While
neutropenia is likely to be the main predisposing factor, several other immune defects have …

TNFα levels are elevated in the marrows of patients with myelodysplastic syndrome (MDS)
and are associated with high rates of apoptosis, which contributes to hematopoietic failure …